{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:19:15Z","timestamp":1794673155850,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["LAB-AECC-2018"],"award-info":[{"award-number":["LAB-AECC-2018"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","award":["B-CTS-480-UGR20, C-EXP-051-UGR23, C-CTS-149-UGR23"],"award-info":[{"award-number":["B-CTS-480-UGR20, C-EXP-051-UGR23, C-CTS-149-UGR23"]}],"id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades Junta de Andalucia","id":[{"id":"https:\/\/ror.org\/05r0vyz12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Missense mutations in the 12\n                    <jats:sup>th<\/jats:sup>\n                    codon of\n                    <jats:italic>KRAS<\/jats:italic>\n                    are key drivers of lung cancer, with glycine-to-cysteine (G12C) and glycine-to-aspartic acid (G12D) substitutions being among the most prevalent. These mutations are strongly associated with poor survival outcomes. Given the critical role of KRAS in lung cancer and other cancers, it remains as a major target for the development of new and complementary treatments. We have developed a CRISPR-High Fidelity (HiFi)-Cas9-based therapy strategy that can effectively and specifically target\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12C<\/jats:italic>\n                    <\/jats:sup>\n                    and\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12D<\/jats:italic>\n                    <\/jats:sup>\n                    mutants, avoiding\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>WT<\/jats:italic>\n                    <\/jats:sup>\n                    off-targeting and affecting KRAS downstream pathways, thereby significantly reducing tumorgenicity. The delivery of HiFiCas9 components via ribonucleoprotein particles (RNPs) and adenovirus (AdV) effectively abrogates cell viability in\n                    <jats:italic>KRAS<\/jats:italic>\n                    -mutant Non-Small Cell Lung Cancer (NSCLC) preclinical models, including 2D and 3D cell cultures, cell-derived xenografts (CDX), and patient-derived xenograft organoids (PDXO). Our in vitro studies demonstrate that HiFiCas9-based therapy achieves superior KRAS inhibition compared to Sotorasib and effectively circumvents certain resistance mechanisms associated with Sotorasib treatment. Moreover, in vivo delivery using adenoviral particles significantly suppresses tumor growth in preclinical NSCLC models. Collectively, our findings establish HiFiCas9 as an effective therapeutic strategy with promising clinical applications, especially if in vivo delivery methods are further optimized.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-62350-4","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:02:29Z","timestamp":1756717349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-311X","authenticated-orcid":false,"given":"Juan Carlos","family":"\u00c1lvarez-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sanju\u00e1n-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-2968","authenticated-orcid":false,"given":"Alberto M.","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Hern\u00e1ndez-Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-0543","authenticated-orcid":false,"given":"Maria S.","family":"Benitez\u2011Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-8964","authenticated-orcid":false,"given":"Alvaro","family":"Andrades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Calabuig-Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7395-4380","authenticated-orcid":false,"given":"Eloisa","family":"Jantus-Lewintre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-7093","authenticated-orcid":false,"given":"Pedro P.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"62350_CR1","unstructured":"Global Cancer Observatory. WHO. Published online 2020. Accessed February 6, 2023. https:\/\/gco.iarc.fr\/today."},{"key":"62350_CR2","first-page":"17","volume":"73","author":"RL Siegel Mph","year":"2023","unstructured":"Siegel Mph, R. L. et al. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"62350_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"62350_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","volume":"41","author":"H Adderley","year":"2019","unstructured":"Adderley, H., Blackhall, F. H. & Lindsay, C. R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 41, 711\u2013716 (2019).","journal-title":"EBioMedicine"},{"key":"62350_CR5","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of ras mutations in cancer. Cancer Res 80, 2669\u20132974 (2020).","journal-title":"Cancer Res"},{"key":"62350_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS Proteins and Their Regulators in Human Disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"62350_CR7","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","volume":"18","author":"S Dogan","year":"2012","unstructured":"Dogan, S. et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res. 18, 6169\u20136177 (2012).","journal-title":"Clin. Cancer Res."},{"key":"62350_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","volume":"14","author":"B El Osta","year":"2019","unstructured":"El Osta, B. et al. Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: The lung cancer mutation consortium experience. J. Thorac. Oncol. 14, 876\u2013889 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"62350_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","volume":"14","author":"N Karachaliou","year":"2013","unstructured":"Karachaliou, N. et al. KRAS mutations in lung cancer. Clin. Lung Cancer 14, 205\u2013214 (2013).","journal-title":"Clin. Lung Cancer"},{"key":"62350_CR10","first-page":"542","volume":"238","author":"M Trahey","year":"1987","unstructured":"Trahey, M. & Mccormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Sci. (1979). 238, 542\u2013545 (1987).","journal-title":"Sci. (1979)."},{"key":"62350_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091\u20131104 (2010).","journal-title":"EMBO J."},{"key":"62350_CR12","unstructured":"Drosten, M. & Barbacid, M. Targeting KRAS mutant lung cancer: light at the end of the tunnel. Mol Oncol. Published online 2021:1-15."},{"key":"62350_CR13","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1101\/gad.947701","volume":"15","author":"GH Fisher","year":"2001","unstructured":"Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249\u20133262 (2001).","journal-title":"Genes Dev."},{"key":"62350_CR14","first-page":"63","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein, I. B. Cancer: Addiction to oncogenes - The Achilles heal of cancer. Science (1979) 297, 63\u201364 (2002).","journal-title":"Science (1979)"},{"key":"62350_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"62350_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578\u2013589.e17 (2018).","journal-title":"Cell"},{"key":"62350_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","volume":"47","author":"JR Chapman","year":"2012","unstructured":"Chapman, J. R., Taylor, M. R. G. & Boulton, S. J. Playing the End Game: DNA Double-Strand Break Repair Pathway Choice. Mol. Cell 47, 497\u2013510 (2012).","journal-title":"Mol. Cell"},{"key":"62350_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med 24, 1216\u20131224 (2018).","journal-title":"Nat. Med"},{"key":"62350_CR20","first-page":"1","volume":"28","author":"G Bender","year":"2021","unstructured":"Bender, G., Fahrioglu Yamaci, R. & Taneri, B. CRISPR and KRAS: a match yet to be made. J. Biomed. Sci. 2021 28:1 28, 1\u201325 (2021).","journal-title":"J. Biomed. Sci. 2021 28:1"},{"key":"62350_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1101\/gr.223891.117","volume":"28","author":"W Kim","year":"2018","unstructured":"Kim, W. et al. Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Res 28, 374\u2013382 (2018).","journal-title":"Genome Res"},{"key":"62350_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"62350_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13062-015-0035-z","volume":"10","author":"V Pliatsika","year":"2015","unstructured":"Pliatsika, V. & Rigoutsos, I. \u201cOff-Spotter\u201d: very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR\/Cas guide RNAs. Biol. Direct 10, 1\u201310 (2015).","journal-title":"Biol. Direct"},{"key":"62350_CR24","doi-asserted-by":"publisher","unstructured":"Xu X., Duan D., Chen S. J. CRISPR-Cas9 cleavage efficiency correlates strongly with targetsgRNA folding stability: From physical mechanism to off-target assessment. Sci Rep. 7, https:\/\/doi.org\/10.1038\/s41598-017-00180-1 (2017).","DOI":"10.1038\/s41598-017-00180-1"},{"key":"62350_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & Van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 42, 168 (2014).","journal-title":"Nucleic Acids Res"},{"key":"62350_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"62350_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2099-x","volume":"580","author":"K Han","year":"2020","unstructured":"Han, K. et al. CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities. Nature 580, 136\u2013141 (2020).","journal-title":"Nature"},{"key":"62350_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"62350_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/jnci\/djr523","volume":"104","author":"NT Ihle","year":"2012","unstructured":"Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst. 104, 228\u2013239 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"62350_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet 53, 86\u201399 (2021).","journal-title":"Nat. Genet"},{"key":"62350_CR31","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"MJ Nokin","year":"2024","unstructured":"Nokin, M. J. et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat. Commun. 15, 1\u201318 (2024).","journal-title":"Nat. Commun."},{"key":"62350_CR33","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.jtho.2021.01.321","volume":"16","author":"B Li","year":"2021","unstructured":"Li, B. et al. PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. J. Thorac. Oncol. 16, S61 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"62350_CR34","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy, G. K. et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of codebreak 100. J. Clin. Oncol. 41, 3311\u20133317 (2023).","journal-title":"J. Clin. Oncol."},{"key":"62350_CR35","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao, M. V. et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 13, 1556\u20131571 (2023).","journal-title":"Cancer Discov."},{"key":"62350_CR36","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.1021\/acsnano.8b01670","volume":"12","author":"SM Kim","year":"2018","unstructured":"Kim, S. M. et al. Simple in vivo gene editing via direct self-assembly of Cas9 ribonucleoprotein complexes for cancer treatment. ACS Nano 12, 7750\u20137760 (2018).","journal-title":"ACS Nano"},{"key":"62350_CR37","doi-asserted-by":"publisher","unstructured":"Lentsch E., et al. CRISPR\/Cas9-mediated knock-out of krasG12D mutated pancreatic cancer cell lines. Int. J. Mol. Sci. 20, https:\/\/doi.org\/10.3390\/ijms20225706 (2019).","DOI":"10.3390\/ijms20225706"},{"key":"62350_CR38","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.7150\/thno.42325","volume":"10","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR\/Cas9 induces efficient tumor regression. Theranostics 10, 5137\u20135153 (2020).","journal-title":"Theranostics"},{"key":"62350_CR39","first-page":"1","volume":"8","author":"W Lee","year":"2018","unstructured":"Lee, W., Lee, J. H., Jun, S., Lee, J. H. & Bang, D. Selective targeting of KRAS oncogenic alleles by CRISPR\/Cas9 inhibits proliferation of cancer cells. Sci. Rep. 8, 1\u20137 (2018).","journal-title":"Sci. Rep."},{"key":"62350_CR40","first-page":"3","volume":"17","author":"C Xu","year":"2019","unstructured":"Xu, C., Li, X., Liu, P., Li, M. & Luo, F. Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine. Oncol. Lett. 17, 3\u201310 (2019).","journal-title":"Oncol. Lett."},{"key":"62350_CR41","doi-asserted-by":"crossref","unstructured":"Spira A. I., et al. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Advanced\/ Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring a KRAS G12C Mutation.; (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.9002"},{"key":"62350_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRAS G12C mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR43","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima, E. C. et al. FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res. 28, 1482\u20131486 (2022).","journal-title":"Clin. Cancer Res."},{"key":"62350_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","volume":"11","author":"JJ Lin","year":"2016","unstructured":"Lin, J. J. et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J. Thorac. Oncol. 11, 556\u2013565 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"62350_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR -Mutated Advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR46","doi-asserted-by":"publisher","unstructured":"Langen A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet. 0. https:\/\/doi.org\/10.1016\/S0140-6736(23)00221-0 (2023).","DOI":"10.1016\/S0140-6736(23)00221-0"},{"key":"62350_CR47","doi-asserted-by":"publisher","unstructured":"Punekar S. R., Shum E., Grello C. M., Lau S. C., Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol. 12, https:\/\/doi.org\/10.3389\/fonc.2022.877594 (2022).","DOI":"10.3389\/fonc.2022.877594"},{"key":"62350_CR48","first-page":"604","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (1979) 351, 604\u2013608 (2016).","journal-title":"Science (1979)"},{"key":"62350_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316\u2013329 (2016).","journal-title":"Cancer Discov."},{"key":"62350_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"62350_CR51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","volume":"25","author":"S Misale","year":"2019","unstructured":"Misale, S. et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25, 796\u2013807 (2019).","journal-title":"Clin. Cancer Res."},{"key":"62350_CR52","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: Insights from In Vitro experiments. J. Thorac. Oncol. 16, 1321\u20131332 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"62350_CR53","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. & Liu, S. Rybkin II, et al. Acquired resistance to KRAS G12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.onc.1201214","volume":"15","author":"E Douville","year":"1997","unstructured":"Douville, E. & Downward, J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene 15, 373\u2013383 (1997).","journal-title":"Oncogene"},{"key":"62350_CR55","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1016\/j.cellsig.2008.08.006","volume":"20","author":"X Li","year":"2008","unstructured":"Li, X., Huang, Y., Jiang, J. & Frank, S. J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell Signal 20, 2145\u20132155 (2008).","journal-title":"Cell Signal"},{"key":"62350_CR56","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to krasg12c inhibition through a novel kras switch-ii pocket mutation and polyclonal alterations converging on ras\u2013mapk reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"62350_CR57","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","volume":"9","author":"EJ Poulin","year":"2019","unstructured":"Poulin, E. J. et al. Tissue-specific oncogenic activity of KRASA146T. Cancer Discov. 9, 738\u2013755 (2019).","journal-title":"Cancer Discov."},{"key":"62350_CR58","doi-asserted-by":"publisher","unstructured":"Mohanty, A. et al. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer. Sci Adv. 9, https:\/\/doi.org\/10.1126\/SCIADV.ADE3816\/SUPPL_FILE\/SCIADV.ADE3816_DATA_FILES_S1_TO_S3.ZIP (2023).","DOI":"10.1126\/SCIADV.ADE3816\/SUPPL_FILE\/SCIADV.ADE3816_DATA_FILES_S1_TO_S3.ZIP"},{"key":"62350_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","volume":"16","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Long-term overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J. Thorac. Oncol. 16, 162\u2013168 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"62350_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.trecan.2022.10.001","volume":"9","author":"M Sattler","year":"2023","unstructured":"Sattler, M., Mohanty, A., Kulkarni, P. & Salgia, R. Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer 9, 42\u201354 (2023).","journal-title":"Trends Cancer"},{"key":"62350_CR61","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon, E. B. et al. Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR62","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"62350_CR63","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083 (2017).","journal-title":"Immunity"},{"key":"62350_CR64","doi-asserted-by":"publisher","unstructured":"Ischenko, I. et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun. 12, https:\/\/doi.org\/10.1038\/S41467-021-21736-W (2021).","DOI":"10.1038\/S41467-021-21736-W"},{"key":"62350_CR65","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","volume":"27","author":"T Mago\u010d","year":"2011","unstructured":"Mago\u010d, T. & Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27, 2957\u20132963 (2011).","journal-title":"Bioinformatics"},{"key":"62350_CR66","doi-asserted-by":"publisher","unstructured":"Chen, S. Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp. iMeta. 2023;2. https:\/\/doi.org\/10.1002\/IMT2.107","DOI":"10.1002\/IMT2.107"},{"key":"62350_CR67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"62350_CR68","doi-asserted-by":"publisher","unstructured":"Oberg, A. L. et al. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Sci Rep. 11, https:\/\/doi.org\/10.1038\/s41598-021-87470-x (2021).","DOI":"10.1038\/s41598-021-87470-x"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62350-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:50:31Z","timestamp":1757335831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62350-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62350"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62350-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7080"}}